Aurintricarboxylic acid

Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC₅₀s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively^[1]. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase^[2]. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis^[3]. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway^[4]. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC₅₀ of 0.6 μM^[5]. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC₅₀ of 0.47 µM^[6]. IC50 & Target: IC50: 8.6 nM (rP2X1R)^[1], 72.9 nM (rP2X3R)^[1], influenza viruses^[2], topoisomerase II^[3], apoptosis^[3] In Vitro: Aurintricarboxylic acid weakly inhibits P2X2/3Rs, P2X2Rs, P2X4Rs or P2X7Rs^[1].
Aurintricarboxylic acid inhibits ATP-induced currents in a concentration dependent manner^[1].
Aurintricarboxylic acid can inhibit the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and vaccinia virus^[2].
Aurintricarboxylic acid inhibits replication of influenza A and B viruses by inhibition of neuraminidase activities^[2].
Aurintricarboxylic acid inhibits TWEAK-Fn14-mediated NF-κB activation^[4].
Aurintricarboxylic acid (10 μM; 0.5-2 hours) suppresses TWEAK-Fn14-mediated NF-κB, Akt, and Src phosphorylation in GBM cells^[4].
Aurintricarboxylic acid represses TWEAK-stimulated glioma cell migration and invasion without causing cell cytotoxicity^[4].
Aurintricarboxylic acid (Compound 8) cannot regulate loading of endogenous let-7 onto AGO2 inside cultured cells, whereas can inhibit RISC loading of exogenous siRNA^[6].